Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) – Research analysts at Cantor Fitzgerald issued their FY2018 earnings per share estimates for Progenics Pharmaceuticals in a research report issued on Sunday, Zacks Investment Research reports. Cantor Fitzgerald analyst M. Goldstein anticipates that the biotechnology company will post earnings of ($0.51) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $15.00 target price on the stock. Cantor Fitzgerald also issued estimates for Progenics Pharmaceuticals’ FY2019 earnings at $0.06 EPS.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Progenics Pharmaceuticals had a negative net margin of 436.08% and a negative return on equity of 87.30%. The business had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.18 million. During the same period in the prior year, the business earned ($0.10) earnings per share. The company’s quarterly revenue was down 15.2% on a year-over-year basis.
A number of other analysts have also issued reports on the stock. BidaskClub upgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 1st. ValuEngine upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 target price on the stock in a research report on Thursday, January 4th. Two analysts have rated the stock with a sell rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $12.35.
Shares of Progenics Pharmaceuticals (PGNX) traded down $0.93 during midday trading on Wednesday, reaching $7.43. 2,823,487 shares of the company were exchanged, compared to its average volume of 1,345,268. Progenics Pharmaceuticals has a 1 year low of $4.60 and a 1 year high of $11.48. The firm has a market capitalization of $607.45, a price-to-earnings ratio of -9.52 and a beta of 3.12. The company has a debt-to-equity ratio of 0.74, a quick ratio of 6.31 and a current ratio of 6.31.
Large investors have recently bought and sold shares of the business. KBC Group NV raised its stake in Progenics Pharmaceuticals by 10.2% during the third quarter. KBC Group NV now owns 234,777 shares of the biotechnology company’s stock worth $1,728,000 after purchasing an additional 21,791 shares during the period. Los Angeles Capital Management & Equity Research Inc. raised its stake in Progenics Pharmaceuticals by 457.2% during the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 88,980 shares of the biotechnology company’s stock worth $655,000 after purchasing an additional 73,010 shares during the period. Cadence Capital Management LLC raised its stake in Progenics Pharmaceuticals by 7.8% during the fourth quarter. Cadence Capital Management LLC now owns 260,046 shares of the biotechnology company’s stock worth $1,547,000 after purchasing an additional 18,770 shares during the period. Gradient Investments LLC raised its stake in Progenics Pharmaceuticals by 36.0% during the fourth quarter. Gradient Investments LLC now owns 74,192 shares of the biotechnology company’s stock worth $441,000 after purchasing an additional 19,630 shares during the period. Finally, Hikari Power Ltd purchased a new position in Progenics Pharmaceuticals during the third quarter worth approximately $1,472,000. 83.67% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Progenics Pharmaceuticals, Inc. Expected to Earn FY2018 Earnings of ($0.51) Per Share (PGNX)” was published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/23/cantor-fitzgerald-weighs-in-on-progenics-pharmaceuticals-inc-s-fy2018-earnings-pgnx.html.
Progenics Pharmaceuticals Company Profile
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.